• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Counterfeit Drugs Task Force February 2004 Update - INTERNATIONAL APPROACH

1. What FDA sought comment on:

  • Strengthening international cooperation in law enforcement efforts, identifying counterfeit products, using anti-counterfeiting technologies, and educating stakeholders and consumers
  • Whether there should be global standards for packaging of pharmaceuticals and the use of anti-counterfeiting technologies

2. What the comments said:

The comments supported FDA involvement in global efforts to deter and detect counterfeit drugs.

3. Discussion:

The growing global prevalence of counterfeit drugs must be curtailed. The steps described in this report are intended to secure the U.S. domestic drug supply. However, as long as counterfeit drugs exist worldwide, opportunities could arise for counterfeit drugs to find their way into the U.S. Many countries have taken steps to secure their nation's drugs supply, while others struggle because of limited resources, inadequate regulatory infrastructure, or competing national health priorities. The World Health Organization (WHO) has taken the lead to increase worldwide collaboration and to develop strategies to deter and detect counterfeit drugs. There are several international criminal enforcement collaborations, such as the Permanent Forum on International Pharmaceutical Crime and the Interpol Intellectual Property Crimes Action Group. FDA intends to work with WHO and other international organizations to develop and implement worldwide strategies to combat counterfeit drugs.

4. FDA Conclusions:

FDA will collaborate with foreign stakeholders to develop strategies to deter and detect counterfeit drugs globally.

Below is a table showing when certain anti-counterfeiting measures will be available:

linked to long descripton of Short and Long Term Anti-Counterfeiting Strategies